Table 1.
Study characteristics.
| Author | SCC Number | AC Number | Study Population | Median Dose (Gy) (Range) | Overall Survival (y: Year) | AE ≥ 3: Total (%) (GI %, Hematology %) |
|---|---|---|---|---|---|---|
| Shirai K, 2011 [12] | 0 | 20 | Japan | 59 (N/A) | 2 y 41% | N/A |
| Li C, 2021 [13] | 3977 | 0 | China | 60 (40–76) | 1 y 69.8% 2 y 46.6% 3 y 37.9% 5 y 30.1% |
N/A |
| Roeder F, 2014 [14] | 22 | 3 | German | 56 (19.2–62) | 1 y 82% 2 y 61% 3 y 56% |
52 (Dysphagia 19, Leukopenia 28) |
| Ge X, 2015 [15] | 112 | 0 | China | N/A (60–66) | 1 y 78.57% 3 y 47.32% |
N/A (Esophagitis 25, Leukopenia 32.14%) |
| La T, 2010 [16] | 6 | 12 | USA | 50.4 (34.2–58.8) | 1 y 79% 2 y 56% |
40 (Esophagitis/Dysphagia 46, Hema 7) |
| Tu L, 2013 [17] | 36 | 0 | China | 60 (52–70) | 1 y 83.3% 2 y 42.8% |
N/A (GI 11.1, Neutropenia 13.9) |
| Gerber N, 2014 [18] | 0 | 41 | USA | N/A (50.4–56) | 2 y 61% | N/A (Esophagitis 12.2, Hema 17.07) |
| Xu Y, 2016 [19] | 69 | 0 | China | N/A (50.4–56) | 1 y 73.8% 2 y 57.4% 3 y 41.0% |
N/A (Esophagitis 14.5, Leukopenia 14.6) |
| Lin S, 2012 [20] | 7 | 25 | USA (Caucasians 95.2%) | 50.4 (N/A) | 3 y 51.7% | N/A (Esophagitis 9.7%, N/A) |
| Takada A, 2016 [21] | 46 | 1 | Japan | 73.4 (64.6–80) | 3 y 59.2% | N/A (Esophagitis 10.6%, Leukopenia 55.3) |
| Freilich J, 2015 [22] | 48 | 184 | USA | N/A (40–60) | 3 y 41.53% | 29.7 (N/A) |
| He L, 2016 [23] | 53 | 317 | USA (white 84.7%) | 50.4 (N/A) | 3 y 37.04% 5 y 25.49% |
N/A (N/A) |
| Yang H, 2017 [24] | 78 | 0 | China | N/A (60–70) | 2 y 56.2% | 15.6 (Dysphagia 12.8, hema 10.24) |
| Iwase H, 2013 [25] | 116 | 0 | Japan | 60 (N/A) | 1 y 78.2% 5 y 29.8% |
N/A (Nausea 3.4, Neutropenia 37.9) |
| Kato K, 2013 [26] | 50 | 1 | Japan | 50.4 (N/A) | 1 y 88.2% 3 y 63.8% |
N/A (Esophagitis 35, Leukopenia 82.3) |
| Nishimura Y, 2012 [27] | 90 | 1 | Japan | 60 (N/A) | 2 y 45% 5 y 28.57% |
16.48 (Esophagitis 2.1, N/A) |
| Kato K, 2011 [28] | 76 | 0 | Japan | 60 (N/A) | 3 y 44.7% 5 y 36.8% |
N/A (Esophagitis 17, Leukocytosis 43) |
| Conroy T, 2014 [29] | 229 | 37 | France | 50 (N/A) | 3 y 23.41% | N/A (Dysphagia 26.64, Neutropenia 28.96) |
| Conroy T, 2010 [30] | 80 | 17 | France | 50 (N/A) | 1 y 67.18% 3 y 37.64% |
73.68 (Dysphagia 17.89, Hema 73.68) |
| Higuchi K, 2014 [31] | 42 | 0 | Japan | 61.2 (12), 50.4 (30) | 1 y 66.1% 3 y 43.9% |
N/A (Esophagitis 28.6, Leukopenia 71.4) |
| Wang H, 2007 [32] | 8 | 16 | USA | 50.4 (N/A) | 3 y 60% | N/A (Nausea 19, Neutropenia 4) |
| Meng X, 2013 [33] | 55 | 0 | China | 59.4 (N/A) | 1 y 92.55% 2 y 75.20% |
N/A (Mucositis 12.7, Neutropenia 32.7) |
| Crosby T, 2013 [34] | 188 | 65 | UK | 50 (N/A) | 2 y 48.65% | N/A (GI 43.5, Hema 24.5) |
| Ishida Y, 2019 [35] | 21 | 0 | Japan | 60 | 3 y 60% 5 y 53.4% |
N/A (Esophagitis 14.29, Neutropenia 28.57) |
| Minsky B, 2002 [8] | 187 | 31 | USA (white 69%, black 24%) | 64.8 vs. 50.4 | 2 y 31% vs. 40% | 76% vs. 71% (N/A) |
| Clavier J, 2011 [36] | 113 | 30 | France | 66 vs. 50 | 2 y 44.7% vs. 50.8% 3 y 36.8% vs. 31.6% 5 y 19.1% vs. 20.7% |
8.43 vs. 6.67 (N/A) |
| Suh Y, 2014 [37] | 117 | 9 | Republic of Korea | >60 (60–75.6) vs. <60 (45–59.4) | 2 y 52.4% vs. 45.2% | N/A (10.4% vs. 8.2%, N/A) |
| Chen C, 2016 [38] | 648 | 0 | China | >60 vs. 50.4 | 5 y 22% vs. 14% | N/A |
| Deng Y, 2017 [39] | 139 | 0 | China | >59.4 vs. 50.4 | 1 y 89% vs. 78% 2 y 61.0% vs. 39.0% 3 y 30% vs. 24% |
N/A (10.5% vs. 2.2%, N/A) |
| Chang C, 2017 [40] | 2061 | 0 | Taiwan | >60 (60–72) vs. <60 (45–59.4) | 2 y 35.47% vs. 26.74% | >2: 22.56% (23.52% vs. 21.78%) |